Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial
Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial have?
Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial has 9 citations in the OpenAlex counts ScholarIQ stores.
When was Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial published?
Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial has 2021 year in the ScholarIQ index.
What is the open-access status of Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial?
Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial has closed oa status in the ScholarIQ index.
What is the DOI of Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial?
The DOI for Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial is on the source record.
What is the OpenAlex record for Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial?
The OpenAlex for Fenfluramine Treatment Improves Everyday Executive Functioning in Patients with Lennox-Gastaut Syndrome: Analysis from a Phase 3 Clinical Trial is on the source record.